A5039577793- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- interferon and immune responses
- Atrial Fibrillation Management and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Chemotherapy-induced cardiotoxicity and mitigation
- Coronary Interventions and Diagnostics
- Viral-associated cancers and disorders
- Multiple and Secondary Primary Cancers
- Vascular Tumors and Angiosarcomas
- Cancer Treatment and Pharmacology
- T-cell and Retrovirus Studies
- Lung Cancer Treatments and Mutations
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Acute Ischemic Stroke Management
- Research on Leishmaniasis Studies
- Acute Lymphoblastic Leukemia research
- Single-cell and spatial transcriptomics
- Ovarian cancer diagnosis and treatment
- Statistical Methods in Clinical Trials
- Chronic Lymphocytic Leukemia Research
Charles University
2014-2024
General University Hospital in Prague
2017-2024
University Hospital in Motol
2024
Early-stage follicular lymphoma (FL) has traditionally been treated with involved-field radiotherapy (RT). Rituximab (R) is a low-toxic, efficient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients stage I–II indolent FL RT (n = 65) or + R 14) alone 14). Median follow-up was 5.0 years RT, 2.8 the subgroup and 2.5 R. The complete response rate 92%, 100% 86% (not significant) median PFS 3.3 years, not reached 4.9 (p...
Background: Dabigatran directly inhibits thrombin and is used in primary secondary stroke prevention individuals with nonvalvular atrial fibrillation. The prodrug dabigatran etexilate absorbed by enteral P-glycoprotein (ABCB1) then activated hepatic intestinal carboxylesterases (CES1) to produce active metabolites. Variations metabolism because of genetics may affect concentration levels clinical outcomes. Study Question: We conducted a study assess how polymorphisms the CES1 (rs2244613)...
This study aimed to evaluate the ability of selected microRNAs as biomarkers atrial fibrillation (AF) in ischemic stroke patients comparison with other established biochemical biomarkers. A prospective case–control consecutive AF admitted a comprehensive center was conducted. The control group consisted no detected on prolonged (at least 3 weeks) Holter ECG monitoring. As potential AF, we analyzed plasma levels (miR-21, miR-29b, miR-133b, miR-142-5p, miR-150, miR-499, and miR-223-3p) 13 at...
Introduction: The ataxia–telangiectasia mutated (ATM) gene plays an important role in the cellular response to DNA damage. Whether different types of ATM aberrations (mutation and/or deletion (del)11q) differentially affect survival mantle cell lymphoma (MCL) has not yet been reported. Methods: We analyzed 160 consecutive MCL patients (pts) treated two Czech university centers (Prague, Olomouc) from 11/2006 12/2021. Both fluorescence situ hybridization (FISH) and next generation sequencing...
Introduction: Burkitt lymphoma (BL) is a rare subtype of non-Hodgkin (NHL) with an aggressive behaviour. The purpose this retrospective study was to analyze the treatment and outcome sporadic BL pts prospectively recorded in Czech Lymphoma Study Group (CLSG) Registry. Methods: NiHiL Registry collects newly diagnosed NHL from majority referral centers. Out 14 047 registered between 1999 2016, 118 (0.84%) were BL. We analyzed 101 clinical characteristics are summarized Table 1. Low-risk...
Introduction: Ageing of lymphoma population becomes the medical problem with growing proportion patients > 60 years. Moreover, term “elderly” is vague comprising people old between 61 to more than 100 We decided analyze prognosis T-cell >60yrs and different age subgroups within this cohort. Methods: used CLSG (Czech Lymphoma Study Group) database (Govtrial NT 03199066) for retrospective analysis, where cohorts were compared according their at diagnosis (<60 yrs, 60-<65, 65-<70, 70-<75, ≥ 75...
Introduction: Patients with relapsed/progressed diffuse large B-cell lymphoma (rDLBCL) survive globally median 12 months since relapse and majority of deaths is attributed to lymphoma. There urgent need efficient therapy for rDLBCL, but clinical trials cannot find up now. Regardless the selection bias inclusion/exclusion criteria in trials, time initiation seems be a critical point trial enrollment. Methods: As data source this retrospective analysis, CLSG (Czech Lymphoma Study Group;...